Halozyme Therapeutics in (halo 0.25 03/01/27)
13F holders, Q2 2024 (June 30)11holders +1
3new positions
2sold out
$0.92avg. 13F price*
At the end of Q2 2024, 11 institutions reported holding Halozyme Therapeutics in (halo 0.25 03/01/27) in their 13F filings, up 1 from Q1 2024. 3 opened new positions and 2 sold out. The largest holders were Sonora Investment Management Group, LLC ($3.7M), Toronto Dominion Bank ($2.9M) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($618K).
- Company
- Halozyme Therapeutics in (halo 0.25 03/01/27)
- CUSIP
- 40637HAD1
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $110K |
| Exits | 2 | $5K |
All 13F filers, Q1 2024 → Q2 2024: 116,000 shares bought and 2,006,364 shares sold, net −1,890,364 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Sonora Investment Management Group, LLC | 0.29% | No change | 4,222,000 | $3.7M |
| Toronto Dominion Bank | 0.00% | Reduce -40.0% | 3,000,000 | $2.9M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.00% | No change | 650,000 | $618K |
| Bank of New York Mellon Corp | 0.00% | No change | 600,000 | $571K |
| Cetera Investment Advisers | 0.00% | No change | 193,000 | $184K |
| &partners | 0.00% | New | 81,000 | $77K |
| Cerity Partners LLC | 0.00% | Reduce -0.5% | 43,000 | $41K |
| Choreo, LLC | 0.00% | New | 28,000 | $26K |
| Lanark Financial, Inc. | 0.00% | No change | 13,000 | $12K |
| Boussard & Gavaudan Investment Management LLP | 0.00% | New | 7,000 | $7K |
| Laffer Tengler Investments, Inc. | 0.00% | Reduce -6.7% | 1,966 | $2K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 0.25 03/01/27)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 0.25 03/01/27) the manager owns.